314P - Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations

N.C Turner,A.D Laird,M.L Telli,H.S Rugo,A Mailliez,J Ettl,E.-M Grischke,L.A Mina,J Balmaña,P.A Fasching,S.A Hurvitz,L.A Albacker,G.M Frampton,J Chelliserry,P Bycott,U Conte,A.M Wardley,M.E Robson

doi:10.1093/annonc/mdz242.009

314P - Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations

N.C Turner, A.D Laird + Show 16 more

Open Access

https://doi.org/10.1093/annonc/mdz242.009

Copy DOI

Journal: Annals of Oncology	Publication Date: Oct 1, 2019
Citations: 1	License type: publisher-specific-oa

Affiliation: Royal Marsden Hospital, Stanford University, Rechts der Isar Hospital, Vall d'Hebron Institute of Oncology, Universitätsklinikum Erlangen, University of Manchester

#Research Grant #Funding Institution + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

314P - Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.